Your browser doesn't support javascript.
loading
Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy.
Kataoka, Kensuke; Oda, Keishi; Takizawa, Hajime; Ogura, Takashi; Miyamoto, Atsushi; Inoue, Yoshikazu; Akagawa, Shinobu; Hashimoto, Seishu; Kishaba, Tomoo; Sakamoto, Koji; Hamada, Naoki; Kuwano, Kazuyoshi; Nakayama, Masayuki; Ebina, Masahito; Enomoto, Noriyuki; Miyazaki, Yasunari; Atsumi, Kenichiro; Izumi, Shinyu; Tanino, Yoshinori; Ishii, Hiroshi; Ohnishi, Hiroshi; Suda, Takafumi; Kondoh, Yasuhiro.
Afiliação
  • Kataoka K; Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan.
  • Oda K; Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan.
  • Takizawa H; Department of Respiratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.
  • Ogura T; Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
  • Miyamoto A; Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan.
  • Inoue Y; Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan.
  • Akagawa S; Department of Respiratory Medicine, National Hospital Organization Tokyo Hospital, Tokyo, Japan.
  • Hashimoto S; Department of Respiratory Medicine, Tenri Hospital, Tenri, Nara, Japan.
  • Kishaba T; Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, Japan.
  • Sakamoto K; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Hamada N; Graduate School of Medical Sciences, Kyushu University, Research Institute for Diseases of the Chest, Fukuoka, Japan.
  • Kuwano K; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Nakayama M; Department of Internal Medicine, Division of Pulmonary Medicine, Jichi Medical University, Shimono, Tochigi, Japan.
  • Ebina M; Department of Respiratory Medicine, Tohoku Medical and Pharmaceutical University Medical School, Sendai, Miyagi, Japan.
  • Enomoto N; Department of Internal Medicine, Second Division, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
  • Miyazaki Y; Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
  • Atsumi K; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Izumi S; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tanino Y; Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Ishii H; Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.
  • Ohnishi H; Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
  • Suda T; Department of Internal Medicine, Second Division, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
  • Kondoh Y; Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan. kondoh@tosei.or.jp.
Sci Rep ; 13(1): 13664, 2023 08 22.
Article em En | MEDLINE | ID: mdl-37608014
While high-level evidence is lacking, numerous retrospective studies have depicted the value of supplemental oxygen in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, and its use should be encouraged where necessary. The clinical course and survival of patients with IPF who have been introduced to oxygen therapy is still not fully understood. The objective of this study was to clarify overall survival, factors associated with prognosis, and causes of death in IPF patients after the start of oxygen therapy. This is a prospective cohort multicenter study, enrolling patients with IPF who started oxygen therapy at 19 hospitals with expertise in interstitial lung disease. Baseline clinical data at the start of oxygen therapy and 3-year follow-up data including death and cause of death were assessed. Factors associated with prognosis were analyzed using univariable and multivariable analyses. One hundred forty-seven eligible patients, of whom 86 (59%) were prescribed ambulatory oxygen therapy and 61 (41%) were prescribed long-term oxygen therapy, were recruited. Of them, 111 died (76%) during a median follow-up of 479 days. The median survival from the start of oxygen therapy was 537 ± 74 days. In the univariable analysis, low body mass index (BMI), low forced vital capacity (FVC), low diffusion capacity (DLCO), resting hypoxemia, short 6 min-walk distance, and high COPD assessment test (CAT) score were significantly associated with poor prognosis. Multivariable analysis revealed low BMI, low FVC, low DLCO, low minimum SpO2 on 6MWT, and high CAT score were independent factors for poor prognosis. The overall survival of IPF patients after starting oxygen therapy is about 1.5 years. In addition to pulmonary function tests, 6MWT and patient reported outcomes can be used to predict prognosis more accurately.Clinical Trial Registration: UMIN000009322.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Fibrose Pulmonar Idiopática Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Fibrose Pulmonar Idiopática Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido